Warning: simplexml_load_file(): rss/gpw_companies_indices.xml:10: parser error : Input is not proper UTF-8, indicate encoding ! Bytes: 0xB3 0x6F 0xB6 0x63 in /equities.pl/klasy/mainpage/EquitiesCompaniesIndices.php on line 15

Warning: simplexml_load_file(): <index><name>ABM Solid SA w upad�o�ci uk�ad</name><short>ABM</short><value_open> in /equities.pl/klasy/mainpage/EquitiesCompaniesIndices.php on line 15

Warning: simplexml_load_file(): ^ in /equities.pl/klasy/mainpage/EquitiesCompaniesIndices.php on line 15
Selvita raises $8.1m ahead of listing on Warsaw Stock Exchange, Equities News - EquitiesPoland.pl
Coverage of high-potential mid-market firms in Poland

Article

Selvita raises $8.1m ahead of listing on Warsaw Stock Exchange

TAG'S: Services (other)

Polish drug discovery company Selvita has successfully completed its Initial Public Offering of 2,651,891 new shares amounting to PLN27.3m (US$8.1m), sold at the maximum announced price.

Selvita says it plans to list new shares on the main market of the Warsaw Stock Exchange, together with 6,413,566 shares previously listed on the NewConnect market, on December 19, 2014.

Selvita operates in two business areas: innovative and service sector. The innovative division is oriented towards the search for novel, original drugs, primarily in the area of oncology, where Selvita cooperates with some of the most renowned drug discovery companies such as H3 Biomedicine, Merck Serono and Felicitex Therapeutics. The drug discovery outsourcing division provides international and Polish pharmaceutical, biotechnology and industrial clients with high-value added and cost efficient research services.

Pawel Przewiezlikowski, co-founder and CEO of Selvita, said, "We are very pleased with investors’ interest in Selvita. The demand among retail and institutional investors has significantly exceeded the number of shares offered. I would like to thank all those who have decided to invest in our Company. Thanks to our new investors, Selvita will be able to develop its projects more rapidly, which will hopefully result in providing more treatment options in areas of high unmet medical need for oncology patients and further dynamic growth of our shareholder value."

The company will use the issue proceeds and Polish government grants to fund an investment program for three major purposes: progressing its products SEL24 and SEL120 through pre-clinical and Phase I development; supporting Selvita’s early stage discovery programs, mainly in oncology; further lab expansion and advanced equipment procurement for Selvita services division.

2014-12-23



Comments : 0

Add comment

The published comments are private opinions of the users. Biznespolska Media Sp. z o.o. is not responsible for their content. Intelligent and insightful comments most appreciated.

Other News

Photo of the week

Photo of the week

Following an impressive run, PKN Orlen fuel reappoints CEO Wojciech Jasiński to spearhead the company to newer, more challenging waters. Gives him a new three year term!

2018-02-23

WSE Indices


NameValueChangeTime
WIG20 2406,11 +0,03 % 17:15
WIG 62665,06 +0,10 % 17:15
sWIG80 14705,88 +0,03 % 17:15
NCIndex 269,08 +0,00 % 17:15

WSE Companies


Top 5 Gainers


Warning: Invalid argument supplied for foreach() in /equities.pl/klasy/mainpage/EquitiesCompaniesIndices.php on line 211

Companies temporarily unavailable

Top 5 Losers


Warning: Invalid argument supplied for foreach() in /equities.pl/klasy/mainpage/EquitiesCompaniesIndices.php on line 223

Companies temporarily unavailable